Collaborations

We sat down with some of the original team members from Schrödinger and Nimbus Therapeutics who led the tyrosine kinase 2 (TYK2) inhibitor program that resulted in NDI-034858, an oral, selective allosteric inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. On December 24, 2022, Takeda

For people with chronic medical conditions, a reliable therapeutic that treats their disease while preserving a good quality of life can be transformative. Patients are thankful when a medication helps relieve symptoms, even if that treatment comes with dosing challenges such as injections or infusions required for most biologic drugs. In our current era of

Chemists encounter many hurdles throughout the innovation process. On one hand, we deal with prolonged experimental timelines to identify materials with target performance profiles, finite resources, and a lack of molecular insights to explain experimental results. On the other hand, we are also challenged by the increasing demand for best materials performance, natural ingredients and

Arguably one of the most important challenges facing the pharma industry today is the efficient adoption of digital platforms to improve the discovery and development of new medicines. At Bayer, we have tackled this challenge with widespread digitalization efforts across our R&D organization, based on the firm belief that we must evolve in order to

Like many things in life, early-stage drug discovery is a numbers game. The more chemical space that can be explored earlier in the discovery process, the greater the likelihood of finding novel, biologically active molecules that meet key parameters for clinical advancement.

When NVIDIA invented the graphics processing unit (GPU) back in the 1990s, it wasn’t just a breakthrough — it was a revolution. GPUs were originally intended to improve computer graphics. They certainly did that, but more realistic video games were just the start.

In 2017, Takeda and Schrödinger joined forces to accelerate the discovery of novel, differentiated therapeutic compounds using Schrödinger’s physics-based computational platform, and having access to Takeda’s deep, innovative expertise and experience in drug discovery.

In 2017, Takeda and Schrödinger joined forces to accelerate the discovery of novel, differentiated therapeutic compounds using Schrödinger’s physics-based computational platform, and having access to Takeda’s deep, innovative expertise and experience in drug discovery.

In late 2019, Schrödinger and AstraZeneca teamed up with the aim of accelerating the discovery of novel therapeutic compounds by improving the throughput of binding affinity predictions.